

Date: 3rd January, 2020

| | |
|---|--|
| To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Scrip Code: APLTLD | To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 533573 |
|---|--|

Dear Sirs,

Subject: Report under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations")

Target Company: Alembic Pharmaceuticals Limited

I, Pranav Chirayu Amin, holding equity shares of Alembic Pharmaceuticals Limited, as part of the promoter group, have acquired from an individual being an immediate relative and also a part of promoter group of Alembic Pharmaceuticals Limited, by way of 'inter-se' transfer, 25.01% equity shares of Nirayu Limited ("Holding Company") which holds 37.15% stake in Alembic Pharmaceuticals Limited as part of the promoter group, which amounts to indirect acquisition of equity shares of Alembic Pharmaceuticals Limited under Regulation 3 read with Regulation 5 of the Takeover Regulations. The said acquisition was pursuant to inter-se transfer of shares amongst qualifying persons as specified in Regulation 10(1)(a)(i) and Regulation 10(1)(a)(ii) of Takeover Regulations.

The Report as prescribed under Regulation 10(6) of the Takeovers Regulations as amended by SEBI Circular No. SEBI/HO/CFD/DCR1/CIR/P/2016/52 dated May 2, 2016 setting out the details of the said indirect acquisition of equity shares of Alembic Pharmaceuticals Limited by way of inter-se transfer is enclosed herewith.

The necessary intimation under Regulation 10(5) of the Takeover Regulations for the said indirect acquisition, in the prescribed format, has already been submitted vide letter dated 26th December, 2019.

Kindly take the information on record.

Thanking you,

Yours faithfully,



Pranav Chirayu Amin

Encl.: As above.

Format for Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

| | | | |
|----|--|---|--|
| 1. | Name of the Target Company (TC) | Alembic Pharmaceuticals Limited | |
| 2. | Name of the acquirer (s) | Pranav Chirayu Amin | |
| 3. | Name of the stock exchange where shares of the TC are listed | BSE Ltd. (BSE) & National Stock Exchange of India Ltd. (NSE) | |
| 4. | Details of the transaction including rationale, if any, for the transfer/ acquisition of shares. | This was an indirect acquisition of equity shares and voting rights of Alembic Pharmaceuticals Limited by the acquirer pursuant to internal restructuring of shareholding of promoter and promoter group. In addition to the below details, please refer Annexure A. | |
| 5. | Relevant regulation under which the acquirer is exempted from making open offer. | 10(1)(a)(i) and 10(1)(a)(ii) | |
| 6. | Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange. | Yes 26 th December, 2019 | |
| 7. | Details of acquisition | Disclosures required to be made under regulation 10(5) | Whether the disclosures under regulation 10(5) are actually made |
| | a. Name of the transferor / seller | Annexure A | Yes |
| | b. Date of acquisition | 2 nd January, 2020 | |
| | c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above | The acquirer has not directly acquired the equity shares of the TC but has acquired the equity shares of Nirayu Limited (“Holding Company”) which holds 37.15% stake in the TC as part of the promoter group. Please refer Annexure A for number of equity shares of the Holding Company which has been acquired by the acquirer. | |

| | | | | | | |
|----|----------------------|--|---|--|---------------------------|--|
| | d. | Total shares actually acquired as a % of diluted share capital of TC | Annexure A | | | |
| | e. | Price at which shares are actually acquired | Nil, as transfer of equity shares of the Holding Company is by way of gift, without consideration through off market transaction. | | | |
| 8. | Shareholding details | | Pre-Transaction | | Post-Transaction # | |
| | | | No. of equity shares held | % w.r.t total equity share capital of TC | No. of equity shares held | % w.r.t total equity share capital of TC |
| | a. | Each Acquirer/Transferee | | | | |
| | | Acquirer (s) | | | | |
| | | Pranav Chirayu Amin | 10,09,800 | 0.54% | 10,09,800 | 0.54% |
| | | Total | 10,09,800 | 0.54% | 10,09,800 | 0.54% |
| | b. | Each Seller/Transferor | | | | |
| | | Malika Chirayu Amin | 30,05,730 | 1.59% | 30,05,730 | 1.59% |
| | | Total | 30,05,730 | 1.59% | 30,05,730 | 1.59% |

As this was an indirect acquisition of the equity shares of the TC, there is no change in direct shareholding of the Acquirer and the Seller in the TC. However, as detailed in Annexure A, the Acquirer has acquired equity shares of the Holding Company, which holds stake in the TC.



Pranav Chirayu Amin
(Acquirer)

Date: 3rd January, 2020
Place: Vadodara

Indirect transfer of equity shares in Alembic Pharmaceuticals Limited amongst promoters and immediate relative thereof (qualifying persons)

| Name of the Company whose equity shares have been transferred | No. of equity shares held in Target Company | % equity holding in the Target Company |
|---|---|--|
| Nirayu Limited (Details given in Note 1) | 7,00,35,435 | 37.15% |
| Total | 7,00,35,435 | 37.15% |

Note 1

Transfer of equity shares of Nirayu Limited

| Particulars | No. of equity shares transferred | % equity holding |
|--------------------------|----------------------------------|------------------|
| Transferor's Name | | |
| Malika Chirayu Amin | 62,275 | 25.01% |
| Total | 62,275 | 25.01% |
| Transferee's Name | | |
| Pranav Chirayu Amin | 62,275 | 25.01% |
| Total | 62,275 | 25.01% |

Note 2

Furthermore, please note that the following acquisitions of the equity shares of the Target Company have also taken place during the Financial Year 2019-20.

As the cumulative direct acquisition of equity shares of the Target Company during the Financial Year 2019-20 was within the limits prescribed under Regulation 3(2) of the Takeover Regulations, the said Regulation was not triggered earlier. Accordingly, there was no requirement under Regulation 10 for making any disclosure at such stage.

| Date of Transfer | Acquirer | Transferor / Seller | No. of equity shares in TC | % of Voting Rights in TC |
|------------------|-------------------------------|------------------------|----------------------------|--------------------------|
| 03.04.2019 | Bhailal Amin General Hospital | Arogyavardhini Society | 2,80,950 | 0.15% |
| 03.04.2019 | Uday Society Education | Vidyanidhi Trust | 8,09,550 | 0.43% |
| 03.04.2019 | Uday Society Education | Utkarsh Vidyakendra | 1,46,250 | 0.08% |
| 03.04.2019 | Uday Society Education | Ujjwal Vidyalaya | 62,250 | 0.03% |

| | | | | |
|--|-----------------------------|-------------------------------------|-----|--------------|
| 25.09.2019 | Alembic City Limited | Purchase of shares from open market | 100 | 0.00% |
| 25.09.2019 | Shreno Publications Limited | Purchase of shares from open market | 100 | 0.00% |
| 25.09.2019 | Laksh Trust | Purchase of shares from open market | 100 | 0.00% |
| 25.09.2019 | Gallup Trust | Purchase of shares from open market | 100 | 0.00% |
| 25.09.2019 | Grace Star Trust | Purchase of shares from open market | 100 | 0.00% |
| 25.09.2019 | Satori Trust | Purchase of shares from open market | 100 | 0.00% |
| 24.12.2019 | Barkha Pranav Amin | Purchase of shares from open market | 100 | 0.00% |
| 24.12.2019 | Krupa Shaunak Amin | Purchase of shares from open market | 100 | 0.00% |
| 24.12.2019 | Shreno Limited | Purchase of shares from open market | 100 | 0.00% |
| Aggregate acquisitions of the equity shares of the Target Company during the Financial Year 2019-20 | | | | 0.69% |
| Aggregate equity shares / voting rights indirectly acquired during the Financial Year through the abovementioned transaction (37.15% * 25.01%) pursuant to which exemption is sought under Regulation 10(1)(a)(i)&(ii) of Takeover Regulations. | | | | 9.29% |